Curi Bio - About the company
Curi Bio is a series B company based in Seattle (United States), founded in 2015. It operates as a Manufacturer of drugs for multiple therapautic areas. Curi Bio has raised $31M in funding from Dynamk Capital and Dream CIS. The company has 160 active competitors, including 66 funded and 8 that have exited. Its top competitors include companies like DNAnexus, Insitro and Immunai Technologies.
Company Details
- Website
- www.curibio.com/
- Social
- Email ID
- *****@curibio.com
- Phone Number
- +1 **********
Key Metrics
Founded Year
2015
Location
Seattle, United States
Stage
Series B
Total Funding
$31M in 16 rounds
Latest Funding Round
Investors
Ranked
13th among 160 active competitors
Employee Count
56 as on Jul 31, 2026
Investment & Acquisitions
Legal entities associated with Curi Bio
Curi Bio is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Curi Bio, Inc. CIN: 473278142 , United States, Active | Dec 31, 1999 | - | 38 (As on Dec 31, 2024) | - |
Sign up to download Curi Bio's company profile
Curi Bio's funding and investors
Curi Bio has raised a total funding of $31M over 16 rounds. Its first funding round was on Sep 01, 2016. Its latest funding round was a Series B round on Dec 03, 2025 for $*****. 1 investor participated in its latest round. Curi Bio has 7 institutional investors.
Here is the list of recent funding rounds of Curi Bio:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Dec 03, 2025 | 3902405 | Series B | 3443258 | 9610448 | 6590146 | 3001124 |
Nov 07, 2025 | 4943539 | Grant (prize money) | 8860956 | 4762886 | 3209284 | |
Sep 25, 2025 | 1104225 | Grant (prize money) | 1002866 | 7219970 | 2592330 |
Access funding benchmarks and valuations. Sign up today!View details of Curi Bio's funding rounds and investors
Curi Bio's founders and board of directors
Founder? Claim ProfileCuri Bio's employee count trend
Curi Bio has 56 employees as of Jul 26. Here is Curi Bio's employee count trend over the years:
Uncover Curi Bio's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Curi Bio's Competitors and alternates
Top competitors of Curi Bio include DNAnexus, Insitro and Immunai Technologies. Here is the list of Top 10 competitors of Curi Bio, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  DNAnexus 2009, Mountain View (United States), Series H | Provider of cloud-based genome informatics & data management platform | $473M | 71/100 | |
2nd |  Insitro 2018, San Francisco (United States), Series C | Developer of machine learning platform for drug discovery and development | $643M | 70/100 | |
3rd | Immunai Technologies 2018, United States, Series B | Developer of next-generation of immunomodulatory therapeutics | $295M | 65/100 | |
4th |  Asimov 2017, Boston (United States), Series B | Provider of integrated suite for advanced genetic design and manufacturing | $234M | 65/100 | |
5th | Metagenomi 2016, Berkeley (United States), Public | Digital gene editing technologies for drug development | $376M | 64/100 | |
6th | Relation 2019, London (United Kingdom), Seed | AI-based drug development tools for researchers | $116M | 64/100 | |
7th | _1569310612679.png?devicePixelRatio=2&height=30&width=30){kind=logo} Kinomica 2017, Macclesfield (United Kingdom), Series A | Provider of a bioinformatics platform for the development of precision medicine | $5.16M | 64/100 | |
8th |  Somite 2023, Boston (United States), Series A | AI-driven platform to produce human tissue for cell-based therapies | $60M | 63/100 | |
9th |  Form Bio 2022, Austin (United States), Series A | Cloud-based data management tool for providers | $30M | 60/100 | |
10th | Graph Therapeutics 2024, Klosterneuburg (Austria), Series A | Provider of AI-based precision immunology technology to develop targeted therapies and biomarkers for immune-driven diseases | $8.1M | 60/100 | |
13th |  Curi Bio 2015, Seattle (United States), Series B | Manufacturer of drugs for multiple therapautic areas | $31M | 57/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Curi Bio's competitors? Click here to see the top ones
Curi Bio's Investments and acquisitions
Curi Bio has acquired Dana Solutions. Curi Bio has not made any investments as of now.Reports related to Curi Bio
Here is the latest report on Curi Bio's geography:
News related to Curi Bio
Filter this listMedia has covered Curi Bio for a total of 5 events in the last 1 year, 2 of them have been about company updates and 1 about partnerships.
•
•
•
Curi Bio Launches Asia-Pacific Hub, Delivering Greater Support to its Growing APAC BusinessBusiness Wire•Jan 12, 2026•Curi Bio
•
•
•
Curi Bio Unlocks Advanced Cardiac Insights with Novoheart IntegrationBusiness Wire•Dec 19, 2024•Curi Bio, Novoheart
•
Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug ScreeningGlobeNewswire•Dec 18, 2024•Novoheart, Curi Bio
•
Curi Bio Recognized as a 2024 Deloitte Technology Fast 500 WinnerBusiness Wire•Nov 23, 2024•Curi Bio
•
Curi Bio to expand into 13,942 square feet of space in Seattle Washington.intelligence360•Sep 11, 2024•Curi Bio
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Curi Bio
Explore our recently published companies
- Trust Rank - India based, 2026 founded, Unfunded company
- LearnSimple - Vancouver based, 2023 founded, Unfunded company
- Danubeblue - Unfunded company
- Mcvdailybrew - Unfunded company
- Ramanaidufilmschool - 2009 founded, Unfunded company
- Nkgberindojaya - 2023 founded, Unfunded company
